New treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) enhance patient care with gene therapies and new mechanisms of action on the horizon, explained Casey Koch, PharmD, from Select Health.
Casey Koch, PharmD
Advertisement
Casey Koch, PharmD, is a clinical pharmacy coordinator at Select Health.
Articles by Casey Koch, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
2
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
3
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
4
AMCP Nexus Bringing the Latest on Health Policy, Drug Access, and Value-Based Care
5
